About bsbh

This author has not yet filled in any details.
So far bsbh has created 209 blog entries.

Health care 2024: Privacy in the age of digital medicine


Duane Schulthess, managing Director of Vital Transformation, was invited as an expert by POLITICO to participate in “Health Care 2024,” a survey-driven series of online debates in which POLITICO will explore how the European Union can best tackle health policy.

In this installment of Health Care 2024 POLITICO asks: Can the EU gain benefits from sharing health data without weakening privacy — and if so, how?

Health care 2024: Privacy in the age of digital medicine2019-07-19T12:25:05+00:00

Tomorrow’s Cures: Impacts of the International Pricing Index

Hosted by GIPC and Vital Transformation

Thursday, July 18, 2019 – 4:00 – 5:00 PM Capitol Hill Visitor’s Center (Room 209-08) First St. NE, Washington, DC 20515

We invite you to join us for a discussion on how the International Pricing Index (IPI) penalizes innovation by targeting companies with the most advanced, newest products. Join GIPC and Vital Transformation to discuss the impacts of IPI on patients, outcomes, and innovation.

Tomorrow’s Cures: Impacts of the International Pricing Index2019-07-19T13:59:44+00:00

Podcast Better Science, Better Health: Erik Tambuyzer Negotiated the First EU Orphan Drug Legislation


Erik Tambuyzer is one of the world’s thought leaders in orphan drugs and rare disease indications. While he was Genzyme’s EU and International Senior Vice-President for Corporate Affairs, he was also the industry’s negotiation lead with the European Commission and Parliament on the Orphan Medicinal Products Regulation, introduced in the year 2000, working together with patients’ organisations and academics.

Podcast Better Science, Better Health: Erik Tambuyzer Negotiated the First EU Orphan Drug Legislation2019-05-27T10:21:54+00:00

BIO 2019-speakers

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation? Wednesday, June 5, 2019 1:45 PM - 2:45 PM BIO International Convention - Philadelphia, PA Speakers Duane Schulthess Managing Director Vital Transformation Peter Young Venture [...]

BIO 2019-speakers2019-05-14T08:29:33+00:00

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation?

Wednesday, June 5, 2019
1:45 PM - 2:45 PM
BIO International Convention - Philadelphia, PA


Following Vital Transformation's research on investment success factors for biotech companies released at the European Health Forum Gastein, this session will present original research modelling the potential impact both short and long term for patients, payers, and industry for such proposals, and show how the IPI can impact access and innovation broadly. As well, our panellists will place the IPI into the context of other models currently being investigated internationally such as value based payments, managed entry agreements, and adaptive pathways.

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation?2019-07-17T10:17:05+00:00

US Biotech Lobby Slams EU Reference Pricing

By CARMEN PAUN 4/9/19,
© POLITICO PRO Healthcare

U.S. biotechnology lobby BIO said the Trump administration’s proposal to peg the prices of certain drugs to a basket of mostly EU reference countries would lead to a “downward spiral” that would negatively affect the development of new medicines.

US Biotech Lobby Slams EU Reference Pricing2019-04-12T13:15:12+00:00

Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets

By Duane Schulthess

It’s odd that a city like Brussels managed to carve itself out a niche as one of the major political centres of the world. The medieval site of a notoriously typhus infested bog, one of the main streets in downtown, ‘Rue du Marais’, literally means, “Street of the Swamp” and the name of the city itself comes from the old Flemish word Broekzele, which roughly translates to ‘settlement in the swamp.’ So, when one talks politically of draining the swamp, at least in Brussels, it carries a literal interpretation that is often distant from the current political climate in DC.

Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets2019-04-12T13:09:35+00:00

Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates

Podcast - Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates EUCOPE is Europe’s principal trade body for small to medium-sized biotechnology companies working in areas often targeting orphan diseases. In this podcast we're joined by Alexander Natz, EUCOPE’s Secretary General, and Delphine Roulland, Senior Manager Public [...]

Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates2019-05-27T10:24:00+00:00

Better Science, Better Health: Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies

Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies Many HTAs in Europe are seen as conservative and even reactionary when it comes to innovating or changing their processes. However, Amr's PhD thesis is a 300+ page ‘how to’ manual highlighting RWE best practices [...]

Better Science, Better Health: Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies2018-11-30T09:28:21+00:00

Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit

Podcast - Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit In this podcast, Steve Bates, the UK BioIndustry Association's CEO, discusses both the challenges and opportunities of Brexit on the UK’s biotechnology sector, and the need for strong, vital IP supported by private investment.Steve was an advisor to [...]

Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit2018-11-19T13:40:26+00:00